Cytokine directed therapy in scleroderma: Rationale, current status, and the future

Current Opinion in Rheumatology

Volumn 14, Issue 6, 2002, Pages 717-722

  Simms, Robert W ^a   Korn, Joseph H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; CYTOKINE ANTIBODY; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GAMMA INTERFERON; HALOFUGINONE; INTERLEUKIN 13; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA;

CYTOKINE RELEASE; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; HUMAN; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 0036838896     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200211000-00015     Document Type: Review

References (50)

1. Jelaska A, Korn JH: Role of apoptosis and transforming growth factor beta 1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000, 43:2230-2239
2. Varga J: Scleroderma and smads: dysfunctional family dynamics culminating in fibrosis. Arthritis Rheum 2002, 46:1703-1713
3. Gruschwitz M, Muller PU, Sepp N, et al.: Transcription and expression of transforming growth factor type beta in the skin progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990, 94:197-203
4. Kikuchi K, Kadono T, Ihn H, et al.: Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. J Invest Dermatol 1995, 105:128-132
5. Kawakami T, Ihn H, Xu W, et al.: Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998, 110:47-51
6. Hoffman BB, Sharma K, Ziyadeh FN: Potential role of TGFB in diabetic nephropathy. J Bone Min Elec Met 1998, 24:190-196
7. Ziyadeh FN, Hoffman BB, Han DC, et al.: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-B antibody in db/db diabetic mice. PNAS 2000, 97:8015-8020
8. Yamamoto T, Takagawa S, Katayama I, et al.: Anti-sclerotic effect of transforming growth factor beta antibody in a mouse model of bleomycinn-induced scleroderma. Clin Immunol 1999, 92:6-13
9. McCormick LL, Zhang Y, Tootell E, et al.: Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999, 163:5693-5699
10. Yata Y, Gotwals P, Koteliansky V, et al.: Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: Implications for antifibrotic therapy. Hepatology 2002, 35:1022-1030
11. Smith JD, Bryant SR, Couper LL, et al.: Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circul Res 1999, 84:1212-1222
12. Frazier K, Williams SDK, Klapper H, et al.: Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996, 107:404-411
13. Igarashi A, Nashiro K, Kikuchi K, et al.: Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996, 106:729-733
14. Gupta S, Clarkson MR, Duggan J, et al.: Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000, 58:1389-1399
15. Allen JT, Knight RA, Bloor CA, et al.: Enhanced insulin-like growth factor binding protein-related protein 2(connective tissue growth factor) expression in patients with idipathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999, 21:693-700
16. Shi-wen X, Pennington D, Holmes A, et al.: Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000, 259:213-224
17. Stratton R, Shi-wen X, Martini G, et al.: Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001, 108:241-250
18. Yokoi H, Mukoyama M, Sugawara A, et al.: Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am J Physiol Renal Physiol 2002, 282:F933-F942
19. Abraham DJ, Shi-wen X, Black CM, et al.: Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000, 275:15220-15225
20. Baggiolini M, Dewald B, Moser B: Human chemokines: an update. Ann Rev Immunol 1997, 15:675-705
21. Llyod CM, Minto AW, Dorf ME, et al.: RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstital fibrosis. J Exp Med 1997, 185:1371-1380
22. Hogaboam CM, Bone-Larson CL, Lipinski S, et al.: Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1 and Th2-type pulmonary granuloma models. J Immunol 1999, 163:2193-2201
23. Zhang Y, McCormick LL, Desai SR, et al.: Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, and immune cell activation. J Immunol 2002, 168:3088-3098
24. Gu L, Tseng S, Horner RM, et al.: Control of Th2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000, 404:407-411
25. Galindo M, Santiago B, Alcami J, et al.: Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) an dIL-8 in human dermal fibroblasts. Clin Exp Immunol 2001, 123:36-41
26. Distler O, Pap T, Kowal-Bielecka O, et al.: Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis. Arthritis Rheum 2001, 44:2665-2678
27. Galindo M, Santiago B, Rivero M, et al.: Chemokine expression by systemic sclerosis fibroblasts. Arthritis Rheum 2001, 44:1382-1386
28. Yamamoto T, Eckes B, Krieg T: High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001, 31:2936-2941
29. Luzina IG, Atamas SP, Wise R, et al.: Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Resp Cell Molec Biol 2002, 26:549-557
30. Postlethwaite AE, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix in response to interleukin 4. J Clin Invest 1992, 90:1479-1485
31. McGaha T, Saito S, Phelps RG, et al.: Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 2001, 116:136-143
32. Ong CJ, Ip S, Teh SJ, et al.: A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999, 196:60-68
33. Ong D, Wong C, Roberts CR, et al.: Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998, 128:2619-2629
34. Kodera T, McGaha TL, Phelps R, et al.: Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-B production by fibroblasts. PNAS' 2002, 99:3800-3805
35. Obiri NI, Leland P, Leonard WJ, et al.: Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995, 270:8797-8804
36. Varela JC, Goldstein MH, Baker HV, et al.: Microarray analysis of gene expression patterns during healing of rat corneas after excimer laser photoreactive keratectomy. Invest Ophthal Vis Sci 2002, 43:1772-1782
37. Thom SB, Myers JS, Rapuano CJ, et al.: Effect of topical anti-transforming growth factor-beta on corneal stromal haze after photorefractive keratectomy in rabbits. J Cataract Refract Surg 1997, 23:1324-1230
38. Shi-Wen X, Denton CP, Dashwood MR, et al,: Fibrobrast matrix gene expression and conective tissue remodeling; role of endothelin-1. J Invest Dermatol 2001, 116:417-425
39. Rubin LJ, Badesh DB, Barst RJ, et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903
40. Gross TJ, Hunninghake GW: Idiopathic pulmonary fibrosis. N Engl J Med 2001, 345:517-525
41. Ziesche R, Hofbauer E, Wittman K, et al.: A preliminary study of long-term treatment with interferon gamma-1-b and low dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2000, 341:1264-1269
42. Freundlich B, Jimenez SA, Steen VD, et al.: Treatment of systemic sclerosis with recombinant interferon-gamma: a phase I/II clinical trial. Arthritis Rheum 1992, 35:1134-1142
43. Granot I, Bartov I, Plavnik I, et al.: Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poultry Sci 1991, 70:1559-1563
44. Yamamoto T, Nishioka K: Analysis of the effect of halofuginone on bleomycin-induced scleroderma. Rheumatology 2002, 41:594-596
45. Nagler A, Firman N, Feferman R, et al.: Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Resp Crit Care Med 1996, 154:1082-1086
46. Pines M, Domb A, Ohana M, et al.: Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochemical Pharmacol 2001, 62:1221-1227
47. Pines M, Knopov V, Genina O, et al.: Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. Hepatology 1997, 27:391-398
48. Granot I, Halevy O, Hurwitz S, et al.: Halofungione: an inhibitor of collagen type I synthesis. Biochimica et Biophysica Act 1993, 1156:107-112
49. Nagler A, Miao HO, Aingorn H, et al.: Inhibition of collagen synthesis, smooth muscle cell proliferation and injury-induced intimal hyperplasia by halofuginone. Art Thromb Vasc Biol 1997, 17:194-202
50. McGaha TL, Phelps RG, Spiera H, et al.: Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002, 118:461-470